Fact CheckerSign in

NCT06786091Completed

Late Side-effects After Cervical Cancer Treatment - Prevention and Treatment

Source: ClinicalTrials.gov · Last updated 21 Aug 2026

Brief summary (registry, in English)

Late side-effects following gynecological cancer are predominantly symptoms from the pelvic region originating from the bowels, urinary tract, lymphatic system, genitals and musculoskeletal system. Pelvic floor dysfunctions such as urinary- and anal incontinence, pelvic organ prolapse, vaginal stenosis as well as compromised sexual function and dyspareunia appear to be highly prevalent. The incidence of gynecological cancer in Norway was 1700 in 2020 and the survival rate in Norway is among the highest in the world. Most women with cervical cancers are treated with curative intension and life expectancy at 5 years after diagnosis is \>80%. A negative impact of pelvic floor disorders on psychosocial well-being and quality of life are seen in survivors of gynecological cancer, and in cancer survivors this is found to be directly linked with patients regaining continence. Pelvic floor muscle training has few or no side effects, and is acknowledged as first line treatment for all types of urinary incontinence in women. Even though less studied, there is evidence to support pelvic floor muscle training as a safe intervention to reduce symptoms of anal incontinence and improve sexual function. A recent comparative cross-sectional study found that survivors of gynecological cancer with dyspareunia had higher stiffness and lower flexibility, coordination and endurance of the pelvic floor muscles compared to women with a history of total hysterectomy but no pelvic pain. These findings suggest a possible role for pelvic floor muscle training in the prevention and treatment of pelvic floor disorders after gynecological cancer. However, the overall quality of evidence for strengthening the pelvic floor muscles to reduce symptoms of pelvic floor dysfunctions after treatment of gynecological cancer is low. This study aims to assess the feasibility of a digital pelvic floor rehabilitation programme led by an experienced pelvic floor physiotherapist. Study subjects are women treated for cervical cancer within the past 5 years, and all included participants will receive the intervention due to the feasibility design. Participants will be assessed clinically at baseline and endpoint, partly to ensure proper pelvic floor muscle contraction. The digital intervention ensures residents in rural areas equal access to specialized pelvic floor rehabilitation.

Status (registry)
Completed
Study type
Interventional
Enrollment
25 (actual)
First submitted
3 Jan 2025
Start date
4 Feb 2025
Primary completion date
10 Feb 2026
Lead sponsor
St. Olavs Hospital
NCT number
NCT06786091

What you commit to

  • Study type: Interventional
  • Participants enrolled: 25
  • From 4 Feb 2025 to the primary completion date, 10 Feb 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • \- Previous pelvic radiation therapy or pelvic surgery.

Who the study is looking for

  • Women diagnosed and treated for cervical cancer (surgery, radiation- or chemo therapy) within the last five years
  • Cancer stadium I-III
  • Adequate knowledge in Norwegian.

Age in the registry: 18 years to 80 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Østfold Hospital
Coordinator of this site? Confirm its status
FredrikstadNorwayUnknown status
St.Olavs University Hopsital
Coordinator of this site? Confirm its status
TrondheimNorwayUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.